EVAX vs NEON vs IMVT vs NKTR vs IOVA

For growth investors, Evaxion Biotech A/S (EVAX) is the stronger pick with 125.

8% revenue growth year-over-year, versus -43. 9% for Nektar Therapeutics (NKTR). Neonode Inc. (NEON) offers the better valuation at 3. 6x trailing P/E, making it the more compelling value choice. Analysts rate Immunovant, Inc. (IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Immunovant, Inc.

(IMVT) delivered a total return of +62. 4%, compared to -98. 8% for Evaxion Biotech A/S (EVAX). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus EVAX's -99. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Neonode Inc.

(NEON) is the lower-risk stock at 0. 94β versus Iovance Biotherapeutics, Inc. 's 2. 01β — meaning IOVA is approximately 113% more volatile than NEON relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 166% for Nektar Therapeutics — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Evaxion Biotech A/S (EVAX) is pulling ahead at 125.

8% versus -43. 9% for Nektar Therapeutics (NKTR). On earnings-per-share growth, the picture is similar: Neonode Inc. grew EPS 224. 4% year-over-year, compared to -45. 2% for Immunovant, Inc.. Over a 3-year CAGR, NKTR leads at -15. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Neonode Inc.

(NEON) is the more profitable company, earning 411. 9% net margin versus -297. 1% for Nektar Therapeutics — meaning it keeps 411. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMVT leads at 0. 0% versus -391. 5% for NEON. At the gross margin level — before operating expenses — NKTR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Neonode Inc.

(NEON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 94)). Iovance Biotherapeutics, Inc. (IOVA) carries a higher beta of 2. 01 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NEON: -91. 1%, IOVA: -34. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (EVAX (Healthcare) and NEON (Technology) and IMVT (Healthcare) and NKTR (Healthcare) and IOVA (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: EVAX is a small-cap high-growth stock; NEON is a small-cap deep-value stock; IMVT is a small-cap quality compounder stock; NKTR is a small-cap quality compounder stock; IOVA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.